74 related articles for article (PubMed ID: 38454937)
1. Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer
Faizan S; Talath S; Wali AF; Hani U; Haider N; Mandal SP; Kumar BRP
RSC Adv; 2024 Apr; 14(16):11368-11387. PubMed ID: 38595721
[TBL] [Abstract][Full Text] [Related]
2. Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.
Nafie MS; Al-Majid AM; Ali M; Alayyaf AA; Haukka M; Ashraf S; Ul-Haq Z; El-Faham A; Barakat A
Front Chem; 2024; 12():1364378. PubMed ID: 38487783
[TBL] [Abstract][Full Text] [Related]
3. Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1
Khedkar NR; Sindkhedkar M; Joseph A
RSC Med Chem; 2024 May; 15(5):1626-1639. PubMed ID: 38784476
[TBL] [Abstract][Full Text] [Related]
4. New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and
Eissa IH; Yousef RG; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Ismail A; Elkady H; Metwaly AM
ACS Omega; 2024 Apr; 9(14):15861-15881. PubMed ID: 38617602
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK
Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523
[TBL] [Abstract][Full Text] [Related]
6. Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.
Ryad N; Elmaaty AA; M Ibrahim I; Ahmed Maghrabi AH; Yahya Alahdal MA; Saleem RM; Zaki I; Ghany LMAA
Future Med Chem; 2024 May; ():. PubMed ID: 38722235
[No Abstract] [Full Text] [Related]
7. New 1,3,4‒oxadiazole Quinazolines as Potential Anticancer Agents: Design, Synthesis, Biological Evaluation, and In silico Studies.
Gujja V; Sadineni K; Koppula SK; Basireddy A; Venkanna B; Gunda SK
Curr Drug Discov Technol; 2024 Apr; ():. PubMed ID: 38616757
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action.
Mohamed FAM; Alakilli SYM; El Azab EF; Baawad FAM; Shaaban EIA; Alrub HA; Hendawy O; Gomaa HAM; Bakr AG; Abdelrahman MH; Trembleau L; Mohammed AF; Youssif BGM
RSC Med Chem; 2023 Apr; 14(4):734-744. PubMed ID: 37122549
[TBL] [Abstract][Full Text] [Related]
9. Novel tropane analogues as Hsp90 inhibitors targeting colon cancer: Synthesis, biological estimation, and molecular docking study.
Almehmadi SJ; Sabour R; Kassem AF; Abbas EMH; Alsaedi AMR; Farghaly TA
Bioorg Chem; 2024 Jun; 150():107497. PubMed ID: 38852311
[TBL] [Abstract][Full Text] [Related]
10. Design, spectroscopic characterizations, and biological investigation of oxospiro[chromine-4,3-indolene]-based compounds as promising antiproliferative EGFR inhibitors and antimicrobial agents.
Alzahrani AYA; Aboelez MO; Kamel MS; Selim HMRM; Alsaggaf AT; Hamd MAE; El-Remaily MAEAAA
Mol Divers; 2024 Jun; ():. PubMed ID: 38851658
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
Zhao F; Lu W; Su F; Xu L; Jiang D; Sun X; Shi J; Zhou M; Lin F; Cao F
Medchemcomm; 2018 Dec; 9(12):2091-2099. PubMed ID: 30746067
[TBL] [Abstract][Full Text] [Related]
12. Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.
Ullah A; Ullah S; Waqas M; Khan M; Rehman NU; Khalid A; Jan A; Aziz S; Naeem M; Halim S; Khan A; Al-Harrasi A
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38616761
[TBL] [Abstract][Full Text] [Related]
13. Coumarin-furo[2,3-
Wang T; Gao Y; Wu F; Luo L; Ma J; Hu Y
RSC Med Chem; 2024 May; 15(5):1565-1577. PubMed ID: 38784474
[TBL] [Abstract][Full Text] [Related]
14. Novel carbazolyl-thiazolyl-chromone and carbazolyl-thiazolyl-pyrazole hybrids: synthesis, cytotoxicity evaluation and molecular docking studies.
Hassanin NM; Ali TE; Assiri MA; Abdel-Kariem SM
RSC Adv; 2024 May; 14(24):17245-17260. PubMed ID: 38808237
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 2-Aryl Indazole: Synthesis, Biological Evaluationand In-Silico Studies.
Krishna Atikala V; Akber Ansari S; Aamer Ansari I; Kapavarapu R; Babu Bollikolla H
Chem Biodivers; 2024 Apr; ():e202302085. PubMed ID: 38666662
[TBL] [Abstract][Full Text] [Related]
16. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
[TBL] [Abstract][Full Text] [Related]
17. Iodoquinazoline-derived VEGFR-2 and EGFR
Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, docking, ADMET and anticancer evaluations of
Alsulaimany M; El-Adl K; Aljohani AKB; Alharbi HY; Alatawi OM; Aljohani MS; El-Morsy A; Almadani SA; Alsimaree AA; Salama SA; Keshek DE; Mohamed AA
RSC Adv; 2023 Dec; 13(51):36301-36321. PubMed ID: 38093733
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis,
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
